Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition

Objectives: We aimed to assess the predictive value of the total metabolic tumor burden prior to treatment in patients with advanced non-small-cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). Methods: Pre-treatment 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudura, Ken, Ritz, Nando, Templeton, Arnoud J., Kutzker, Tim, Foerster, Robert, Antwi, Kwadwo, Kreissl, Michael C., Hoffmann, Martin H. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253507/
https://www.ncbi.nlm.nih.gov/pubmed/37297920
http://dx.doi.org/10.3390/jcm12113725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253507/
https://www.ncbi.nlm.nih.gov/pubmed/37297920
http://dx.doi.org/10.3390/jcm12113725

Ejemplares similares